Chinese expert consensus on targeted therapy for colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2022.05.001

Abstract

Abstract:

In recent years, with the application of new targeted drugs, it has become a first-line scheme for individualized and comprehensive treatment of colorectal cancer. Colorectal Cancer Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Expert Committee on Quality Control of Colorectal Cancer of Center National Cancer/National Cancer Quality Control Center organized many experts nationwide to discuss the standardized application of colorectal cancer targeted drugs.

Key words: Colorectal neoplasms, Targeted drugs, Chemotherapy, Efficacy, Adverse reactions

Colorectal Cancer Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Expert Committee on Quality Control of Colorectal Cancer of Center National Cancer/National Cancer Quality Control Center. Chinese expert consensus on targeted therapy for colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(05): 353-360.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2022.05.001

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2022/V11/I05/353

References 22

[1]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022, 2(1): 1-9.
[2]	Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today[DB/OL]. Lyon, France: International Agency for Research on Cancer. accessed[15032020]. URL
[3]	Beppu T, Emi Y, Tokunaga S, et al. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study)[J]. Anticancer Res, 2014, 34(11): 6655-6662.
[4]	Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[5]	王延召, 雷福明. 结直肠癌靶向药物治疗[J]. 实用临床医学, 2016, 17(3): 101-103.
[6]	姜帅, 蔡晧东, 董梅. 应重视对新型抗肿瘤药物不良反应的监测[J]. 药物不良反应杂志, 2020, 22(4): 217-220.
[7]	Fuchs CS, Tomasek J, Yong CJ, et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911): 31-39.
[8]	Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235.
[9]	Strumberg D, Schultheis B. Regorafenib for cancer[J]. Expert Opin Investig Drugs, 2012, 21(6): 879-889.
[10]	Roper J, Sinnamon MJ, Coffee EM, et al. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer[J]. Cancer Lett, 2014, 347:204-211.
[11]	Kim D, Xue JY, Lito P. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients[J]. Cell, 2020, 183(4): 850-859.
[12]	Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors[J]. N Engl J Med, 2020, 383(13): 1207-1217.
[13]	Jones JC, Renfro LA, Al-Shamsi HO, et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer[J]. J Clin Oncol, 2017, 35(23): 2624-2630.
[14]	Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine[J]. J Clin Oncol, 2013, 31(20):2554-2562.
[15]	Jiang W, Cai MY, Li SY, et al. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features[J]. Int J Cancer, 2019, 144(9): 2161-2168.
[16]	Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer[J]. Cancer Cell, 2018, 33(1): 125-136.e3.
[17]	Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer[J]. Oncologist, 2019, 24(10): 1395-1402.
[18]	Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(6): 738-746.
[19]	Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2019, 20(4): 518-530.
[20]	Guo Y, Guo XL, Wang S, et al. Genomic alterations of NTRK, POLE, ERBB2, and microsatellite instability status in Chinese patients with colorectal cancer[J]. Oncologist, 2020, 5(11): e1671-e1680.
[21]	Wang H, Li ZW, Ou Q, et al. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability[J]. Cancer Med, 2022, 11(13): 2541-2549.
[22]	Wollina U. Update of cetuximab for non-melanoma skin cancer[J]. Expert Opin Biol Ther, 2014, 14(2): 271-276.

Please choose a citation manager

Content to export